Page 168 of 449: studies 1,671 to 1,680 of 4,483, newest first. Back to the ketamine overview
JAMA Network Open May 1, 2023 R. Price, M. Wallace, S. Mathew et al. 9 citations
This secondary analysis of a randomized clinical trial examines whether automated self-association training can prolong the antidepressant effect of a single infusion of ketamine beyond 1 month in patients with treatment-resistant depression.
Behavioural Brain Research May 1, 2023 S. Kantor, Michael Lanigan, Lauren Giggins et al. 11 citations
Wistar-Kyoto (WKY) rats exhibit depression-like characteristics and decreased sensitivity to monoamine-based antidepressants, making them a suitable model of treatment-resistant depression (TRD). Ketamine has emerged recently as a rapidly acting antidepressant with high efficacy in TRD. Our aim was to determine whether subanaesthetic doses of ketamine can correct sleep and electroencephalogram...
Pharmacology & Therapeutics May 1, 2023 J. Johnston, Ioline D. Henter, Carlos A. Zarate 106 citations
Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist first developed as an anesthetic, has shown significant promise as a medication with rapid antidepressant properties in treatment-resistant depression. However, concerns such as adverse side effects and potential misuse liability have limited its widespread use. Racemic ketamine has two enantiomers—(S)- and (R)-ketamine—that appear...
Cureus May 1, 2023 Michael Kelson, Justin M Burnett, Amy Matthews et al. 32 citations
Alcohol use disorder (AUD) is a chronic, recurrent condition that demonstrates significant heterogeneity in treatment response to first-line agents. Ketamine may have a therapeutic role in substance use disorders; however, research on this topic is limited. The objective of this systematic review is to qualitatively synthesize the current evidence of ketamine treatment for alcohol use disorder...
medRxiv Preprint Server April 28, 2023 Theresa R. Lii, Ashleigh E. Smith, Josephine R. Flohr et al. 28 citations preprint
Abstract BACKGROUND Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials. METHODS In a triple-masked, randomized, placebo-controlled trial, 40 adult patients with major depressive disorder were randomized to a single infusion of ketamine (0.5 mg/kg) or placebo (saline) during anesthesia as usual for routine...
Frontiers in Psychiatry April 27, 2023 Charlotte Goldfine, Jeremiah J. Tom, Dana D. Im et al. 30 citations
Introduction: Alcohol use disorder (AUD) is the most prevalent substance use disorder (SUD) globally. In 2019, AUD affected 14.5 million Americans and contributed to 95,000 deaths, with an annual cost exceeding 250 billion dollars. Current treatment options for AUD have moderate therapeutic effects and high relapse rates. Recent investigations have demonstrated the potential efficacy of...
The American journal of case reports April 25, 2023 Elizabeth A Gregor, Wanhong Zheng
BACKGROUND Benzodiazepines and electroconvulsive therapy (ECT) are standard treatment options for catatonia, a life-threatening psychomotor syndrome in people with serious mental illness. The purpose of this study was to discuss the use of ketamine in treatment-resistant catatonia, which has not been established in current literature. CASE REPORT A 63-year-old woman with schizoaffective...
Journal of Clinical Case Reports Medical Images and Health Sciences April 21, 2023 Bouchra Hallab
Ketamine is a " dissociative anaesthetic " with fast analgesic and amnesic properties that has been used since more than 40 years. Today, ketamine abuse has become a public health concern. We report the case of a 23-year-old patient who came to the Casablanca Addictology Centre asking for help with ketamine abuse. At the interview the patient presented depressive symptoms and had already made 3...
Pharmaceuticals April 21, 2023 Thi Mai Loan Nguyen, Fabrice Jollant, Laurent Tritschler et al.
Around 700,000 people die from suicide each year in the world. Approximately 90% of suicides have a history of mental illness, and more than two-thirds occur during a major depressive episode. Specific therapeutic options to manage the suicidal crisis are limited and measures to prevent acting out also remain limited. Drugs shown to reduce the risk of suicide (antidepressants, lithium, or...
Neuropsychopharmacology April 19, 2023 N. Murphy, Amanda J. F. Tamman, Marijn Lijffijt et al. 18 citations
Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD). The proposed mechanism of antidepressant effects of ketamine is a glutamatergic surge, which can be measured by electroencephalogram (EEG) gamma oscillations. Yet, non-linear EEG biomarkers of ketamine effects such as neural complexity are needed to capture broader systemic effects,...